Liudmila Cebotaru
Overview
Explore the profile of Liudmila Cebotaru including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1029
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ciobanu C, Yanda M, Zeidan A, Izzi J, Guggino W, Cebotaru L
Gene Ther
. 2024 Jul;
31(9-10):499-510.
PMID: 39069560
Gene therapy for CF has concentrated on targeting the lung. Here we took a different approach by injecting into the cephalic vein and spraying into the trachea of G551D, CF...
2.
Yanda M, Zeidan A, Ciobanu C, Izzi J, Guggino W, Cebotaru L
Hum Gene Ther
. 2023 Aug;
34(21-22):1135-1144.
PMID: 37650819
Cystic fibrosis (CF) is potentially treatable by gene therapy. Since the identification of the CF gene, preclinical and clinical trials have concentrated on achieving effective gene therapy targeting the lung....
3.
Yanda M, Ciobanu C, Guggino W, Cebotaru L
Am J Physiol Cell Physiol
. 2023 Jul;
325(3):C682-C693.
PMID: 37519231
Defects in the primary cilium are associated with autosomal dominant polycystic kidney disease (ADPKD). We used a combination of animal models, Western blotting, and confocal microscopy and discovered that CFTR...
4.
Yanda M, Zeidan A, Cebotaru L
Am J Physiol Gastrointest Liver Physiol
. 2023 Mar;
324(5):G404-G414.
PMID: 36880660
Systemic and portal hypertension, liver fibrosis, and hepatomegaly are manifestations associated with autosomal recessive polycystic kidney disease (ARPKD), which is caused by malfunctions of fibrocystin/polyductin (FPC). The goal is to...
5.
Yanda M, Tomar V, Cole R, Guggino W, Cebotaru L
Cell Calcium
. 2021 Nov;
101:102501.
PMID: 34823104
Mutations in either of the polycystic kidney disease genes, PKD1 or PKD2, engender the growth of cysts, altering renal function. Cystic growth is supported by major changes in cellular metabolism,...
6.
Yanda M, Tomar V, Cebotaru C, Guggino W, Cebotaru L
Hum Gene Ther
. 2021 Nov;
33(3-4):131-147.
PMID: 34806411
Repeat dosing poses a major hurdle for the development of an adeno-associated virus (AAV)-based gene therapy for cystic fibrosis, in part because of the potential for development of an immune...
7.
Yanda M, Cebotaru L
FASEB J
. 2021 Oct;
35(11):e21987.
PMID: 34662459
Autosomal dominant polycystic kidney disease (ADPKD) is associated with the formation of renal cysts. We have devised a therapeutic approach, based on reversing the cyst phenotype from secretion to absorption...
8.
Yao Q, Outeda P, Xu H, Walker R, Basquin D, Qian F, et al.
FASEB J
. 2021 Sep;
35(10):e21865.
PMID: 34486178
Autosomal dominant polycystic kidney disease is a common inherited renal disorder that results from mutations in either PKD1 or PKD2, encoding polycystin-1 (PC1) and polycystin-2 (PC2), respectively. Downregulation or overexpression...
9.
Yanda M, Tomar V, Cebotaru L
Cell Mol Gastroenterol Hepatol
. 2021 Jul;
12(5):1517-1529.
PMID: 34329764
Background & Aims: Autosomal recessive polycystic kidney disease (ARPKD) is caused by mutations in PKHD1, encoding fibrocystin/polyductin (FPC). Severe disease occurs in perinates. Those who survive the neonatal period face...
10.
Peruchetti D, Barahuna-Filho P, Silva-Aguiar R, Abreu T, Takiya C, Cheng J, et al.
Biochim Biophys Acta Gen Subj
. 2021 Jun;
1865(9):129950.
PMID: 34144121
Background: Tubule-interstitial injury (TII) is one of the mechanisms involved in the progression of renal diseases with progressive proteinuria. Angiotensin II (Ang II) type 1 receptor blockers (ARBs) have been...